Onconova Therapeutics, Inc.

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). The Company has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. Advanced clinical trials with the Company’s lead compounds, IV and oral rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. In addition to rigosertib, Onconova is in pre-clinical development with ON 123300, a combination CDK4/6 and ARK5 inhibitor. Onconova is targeting additional solid tumor settings and medical indications as well.
Ticker:
ONTX
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
1998
Main Therapeutic Focus:
Lead Product in Development:
rigosertib
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Vice President, Corporate Development
Onconova Therapeutics, Inc.